{
  "_originalData": {
    "title": "Fusobacterium necrophorum",
    "lastUpdated": "Jan 6, 2025",
    "clinicalInfo": {
      "links": [
        "Lemierre's Syndrome (suppurative jugular vein phlebitis often with systemic emboli)",
        "Pharyngitis, Tonsillitis",
        "Hepatic Abscess",
        "Brain Abscess, Bacterial",
        "Sinusitis, chronic",
        "Actinomycosis, cervico-facial",
        "Bite: Dog"
      ],
      "treatmentBasis": {
        "title": "The basis of treatment of F. necrophorum is based on scant recent phenotypic susceptibility tests and small clinical observational case series",
        "notes": [
          "Clinical response is key as phenotypic in vitro susceptibility testing may not be done",
          "Only a few labs can, or will, do whole genome sequencing to detect resistance genes",
          "Earlier reports detected the production of penicillinase in 20% of strains; the beta-lactamases are inhibited by the clavulanate in amoxicillin-clavulanate and the tazobactam in piperacillin-tazobactam",
          "All Fusobacterium species are resistant to macrolide antibiotics",
          "All Fusobacterium species are sensitive to the carbapenems",
          "A few strains of F. necrophorum reported resistant in vitro to metronidazole"
        ]
      }
    },
    "classification": {
      "description": "Gram negative bacillus, anaerobic"
    },
    "regimens": {
      "primary": {
        "notes": [
          "Often need surgical drainage and debridement"
        ],
        "options": [
          "Metronidazole 500 mg IV/po q8h + Ceftriaxone 2 gm IV q24h",
          "Piperacillin-tazobactam 4.5 gm IV (over 4 hr) q8h"
        ]
      },
      "alternative": {
        "options": [
          "Imipenem-cilastatin 500 mg IV q6h or Meropenem 0.5-1 gm IV q8h",
          "Clindamycin 600-900 mg IV q8h"
        ]
      }
    },
    "comments": [
      "Fusobacterium sp. are part of normal flora of mouth (primarily), GI tract, female GU tract.",
      "Found (often with other mouth flora) in dental abscesses, peritonsillar abscesses and other forms of oro-pharyngeal sepsis.",
      "Striking propensity (usually as complication of peritonsillar abscess) to cause septic jugular thrombosis with bacteremia and metastatic abscesses (Lemierre's syndrome) (Lancet Infect Dis 12:808, 2012).",
      "4-23% produce ß-lactamase (Ped Infect Dis J 12:532, 1993).",
      "Pharyngitis/tonsillitis: in one study, infection with F. necrophorum was twice as common as Group A strep.; clinically resembles streptococcal pharyngitis (Ann Intern Med 162:241, 2015).",
      "Detected by PCR but, at present, no commercial assay available",
      "Like GpA streptococcus, can be present in asymptomatic carriage state",
      "Re: potential role as a pathogen, see Ann Intern Med 162:876, 2015; PLoS ONE 13:e0189423. 2018; J Clin Micro 2017;55:1147",
      "Treatment for patient with severe IgE mediated anaphylaxis to beta-lactams: metronidazole OR clindamycin; in vitro resistance to either is very rare (Perry, M et al. Anaerobe.2023 Apr; 80: 102717)",
      "Review: Anaerobe 2016; 42:89"
    ]
  },
  "_metadata": {
    "originalKeys": [
      "title",
      "lastUpdated",
      "clinicalInfo",
      "classification",
      "regimens",
      "comments"
    ],
    "conversionTimestamp": "2025-07-15T03:45:00.000Z",
    "sourceFormat": "legacy_reference"
  },
  "identity": {
    "bacteriumName": {
      "sources": ["title"],
      "value": "Fusobacterium necrophorum"
    },
    "aliases": {
      "sources": ["aliases"],
      "value": []
    },
    "lastUpdated": {
      "sources": ["lastUpdated"],
      "value": "Jan 6, 2025"
    },
    "classification": {
      "sources": ["classification"],
      "value": {
        "description": "Gram negative bacillus, anaerobic"
      }
    }
  },
  "clinicalInformation": {
    "summary": {
      "sources": ["clinicalInfo.links"],
      "value": "Associated with Lemierre's Syndrome, pharyngitis, hepatic abscess, brain abscess, sinusitis, and other infections"
    },
    "clinicalSetting": {
      "sources": ["clinicalInfo"],
      "preservedStructure": {
        "originalFormat": "object",
        "content": {
          "links": [
            "Lemierre's Syndrome (suppurative jugular vein phlebitis often with systemic emboli)",
            "Pharyngitis, Tonsillitis",
            "Hepatic Abscess",
            "Brain Abscess, Bacterial",
            "Sinusitis, chronic",
            "Actinomycosis, cervico-facial",
            "Bite: Dog"
          ],
          "treatmentBasis": {
            "title": "The basis of treatment of F. necrophorum is based on scant recent phenotypic susceptibility tests and small clinical observational case series",
            "notes": [
              "Clinical response is key as phenotypic in vitro susceptibility testing may not be done",
              "Only a few labs can, or will, do whole genome sequencing to detect resistance genes",
              "Earlier reports detected the production of penicillinase in 20% of strains; the beta-lactamases are inhibited by the clavulanate in amoxicillin-clavulanate and the tazobactam in piperacillin-tazobactam",
              "All Fusobacterium species are resistant to macrolide antibiotics",
              "All Fusobacterium species are sensitive to the carbapenems",
              "A few strains of F. necrophorum reported resistant in vitro to metronidazole"
            ]
          }
        }
      }
    }
  },
  "treatmentData": {
    "_treatmentMetadata": {
      "originalFormat": "legacy_reference",
      "hasComplexCombinations": true,
      "hasOptionsArray": true
    },
    "standardizedRegimens": [
      {
        "regimenId": "primary-combination-1",
        "extractedFrom": "regimens.primary.options[0]",
        "context": {
          "type": "directed",
          "condition": "Primary treatment for Fusobacterium necrophorum infection"
        },
        "preference": "primary",
        "strategy": "combination",
        "drugs": [
          {
            "drugName": "Metronidazole",
            "dose": "500 mg",
            "route": "IV/po",
            "frequency": "q8h",
            "originalText": "Metronidazole 500 mg IV/po q8h"
          },
          {
            "drugName": "Ceftriaxone",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q24h",
            "originalText": "Ceftriaxone 2 gm IV q24h"
          }
        ],
        "clinicalNotes": [
          "Often need surgical drainage and debridement"
        ],
        "originalFormat": {
          "type": "combination_option",
          "preservedContent": "Metronidazole 500 mg IV/po q8h + Ceftriaxone 2 gm IV q24h"
        }
      },
      {
        "regimenId": "primary-single-1",
        "extractedFrom": "regimens.primary.options[1]",
        "context": {
          "type": "directed",
          "condition": "Primary treatment for Fusobacterium necrophorum infection"
        },
        "preference": "primary",
        "strategy": "monotherapy",
        "drugs": [
          {
            "drugName": "Piperacillin-tazobactam",
            "dose": "4.5 gm",
            "route": "IV",
            "frequency": "q8h",
            "administrationNotes": "over 4 hr",
            "originalText": "Piperacillin-tazobactam 4.5 gm IV (over 4 hr) q8h"
          }
        ],
        "clinicalNotes": [
          "Often need surgical drainage and debridement"
        ],
        "originalFormat": {
          "type": "single_option",
          "preservedContent": "Piperacillin-tazobactam 4.5 gm IV (over 4 hr) q8h"
        }
      },
      {
        "regimenId": "alternative-carbapenem-1",
        "extractedFrom": "regimens.alternative.options[0]",
        "context": {
          "type": "directed",
          "condition": "Alternative treatment for Fusobacterium necrophorum infection"
        },
        "preference": "alternative",
        "strategy": "choice",
        "drugChoices": [
          {
            "drugName": "Imipenem-cilastatin",
            "dose": "500 mg",
            "route": "IV",
            "frequency": "q6h",
            "originalText": "Imipenem-cilastatin 500 mg IV q6h"
          },
          {
            "drugName": "Meropenem",
            "dose": "0.5-1 gm",
            "route": "IV",
            "frequency": "q8h",
            "originalText": "Meropenem 0.5-1 gm IV q8h"
          }
        ],
        "originalFormat": {
          "type": "choice_option",
          "preservedContent": "Imipenem-cilastatin 500 mg IV q6h or Meropenem 0.5-1 gm IV q8h"
        }
      },
      {
        "regimenId": "alternative-single-1",
        "extractedFrom": "regimens.alternative.options[1]",
        "context": {
          "type": "directed",
          "condition": "Alternative treatment for Fusobacterium necrophorum infection"
        },
        "preference": "alternative",
        "strategy": "monotherapy",
        "drugs": [
          {
            "drugName": "Clindamycin",
            "dose": "600-900 mg",
            "route": "IV",
            "frequency": "q8h",
            "originalText": "Clindamycin 600-900 mg IV q8h"
          }
        ],
        "originalFormat": {
          "type": "single_option",
          "preservedContent": "Clindamycin 600-900 mg IV q8h"
        }
      }
    ],
    "referenceBasedTreatments": {
      "primaryRegimens": {
        "originalFormat": "object",
        "content": {
          "notes": [
            "Often need surgical drainage and debridement"
          ],
          "options": [
            "Metronidazole 500 mg IV/po q8h + Ceftriaxone 2 gm IV q24h",
            "Piperacillin-tazobactam 4.5 gm IV (over 4 hr) q8h"
          ]
        }
      },
      "alternativeRegimens": {
        "originalFormat": "object",
        "content": {
          "options": [
            "Imipenem-cilastatin 500 mg IV q6h or Meropenem 0.5-1 gm IV q8h",
            "Clindamycin 600-900 mg IV q8h"
          ]
        }
      }
    }
  },
  "additionalData": {
    "comments": {
      "sources": ["comments"],
      "preservedStructure": {
        "originalFormat": "array",
        "content": [
          "Fusobacterium sp. are part of normal flora of mouth (primarily), GI tract, female GU tract.",
          "Found (often with other mouth flora) in dental abscesses, peritonsillar abscesses and other forms of oro-pharyngeal sepsis.",
          "Striking propensity (usually as complication of peritonsillar abscess) to cause septic jugular thrombosis with bacteremia and metastatic abscesses (Lemierre's syndrome) (Lancet Infect Dis 12:808, 2012).",
          "4-23% produce ß-lactamase (Ped Infect Dis J 12:532, 1993).",
          "Pharyngitis/tonsillitis: in one study, infection with F. necrophorum was twice as common as Group A strep.; clinically resembles streptococcal pharyngitis (Ann Intern Med 162:241, 2015).",
          "Detected by PCR but, at present, no commercial assay available",
          "Like GpA streptococcus, can be present in asymptomatic carriage state",
          "Re: potential role as a pathogen, see Ann Intern Med 162:876, 2015; PLoS ONE 13:e0189423. 2018; J Clin Micro 2017;55:1147",
          "Treatment for patient with severe IgE mediated anaphylaxis to beta-lactams: metronidazole OR clindamycin; in vitro resistance to either is very rare (Perry, M et al. Anaerobe.2023 Apr; 80: 102717)",
          "Review: Anaerobe 2016; 42:89"
        ]
      }
    },
    "allOtherKeys": {}
  }
}